PMID- 25369529
OWN - NLM
STAT- MEDLINE
DCOM- 20150701
LR  - 20211203
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 11
DP  - 2014
TI  - YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian 
      cancer initiated cells.
PG  - e109575
LID - 10.1371/journal.pone.0109575 [doi]
LID - e109575
AB  - Recent evidence suggests that some solid tumors, including ovarian cancer, 
      contain distinct populations of stem cells that are responsible for tumor 
      initiation, growth, chemo-resistance, and recurrence. The Hippo pathway has 
      attracted considerable attention and some investigators have focused on YAP 
      functions for maintaining stemness and cell differentiation. In this study, we 
      successfully isolated the ovarian cancer initiating cells (OCICs) and 
      demonstrated YAP promoted self-renewal of ovarian cancer initiated cell (OCIC) 
      through its downstream co-activator TEAD. YAP and TEAD families were required for 
      maintaining the expression of specific genes that may be involved in OCICs' 
      stemness and chemoresistance. Taken together, our data first indicate that 
      YAP/TEAD co-activator regulated ovarian cancer initiated cell pluripotency and 
      chemo-resistance. It proposed a new mechanism on the drug resistance in cancer 
      stem cell that Hippo-YAP signal pathway might serve as therapeutic targets for 
      ovarian cancer treatment in clinical.
FAU - Xia, Yan
AU  - Xia Y
AD  - Assisted Reproductive Centre, Shaanxi Maternal and Child Care Service Hospital, 
      Xi'an, China; Life Sciences Institute and Innovation Center for Cell Biology, 
      Zhejiang University, Hangzhou, China.
FAU - Zhang, Yin-Li
AU  - Zhang YL
AD  - Life Sciences Institute and Innovation Center for Cell Biology, Zhejiang 
      University, Hangzhou, China.
FAU - Yu, Chao
AU  - Yu C
AD  - Life Sciences Institute and Innovation Center for Cell Biology, Zhejiang 
      University, Hangzhou, China.
FAU - Chang, Ting
AU  - Chang T
AD  - Department of Neurology, Tangdu Hospital, the Fourth Military Medical University, 
      Xi'an, China.
FAU - Fan, Heng-Yu
AU  - Fan HY
AD  - Life Sciences Institute and Innovation Center for Cell Biology, Zhejiang 
      University, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141104
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (ABCB1 protein, human)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B)
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (TEA Domain Transcription Factors)
RN  - 0 (TEAD1 protein, human)
RN  - 0 (Transcription Factors)
RN  - 0 (YAP-Signaling Proteins)
RN  - 0 (YAP1 protein, human)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - EC 2.7.11.26 (Glycogen Synthase Kinase 3)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B/metabolism
MH  - Adaptor Proteins, Signal Transducing/antagonists & 
      inhibitors/genetics/*metabolism
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cell Survival/drug effects
MH  - DNA-Binding Proteins/antagonists & inhibitors/genetics/*metabolism
MH  - Drug Resistance, Neoplasm/drug effects
MH  - Female
MH  - Glycogen Synthase Kinase 3/metabolism
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - Neoplastic Stem Cells/cytology/*metabolism
MH  - Nuclear Proteins/antagonists & inhibitors/genetics/*metabolism
MH  - Ovarian Neoplasms/drug therapy/metabolism/pathology
MH  - Phosphoproteins/antagonists & inhibitors/genetics/*metabolism
MH  - RNA Interference
MH  - Signal Transduction
MH  - TEA Domain Transcription Factors
MH  - Transcription Factors/antagonists & inhibitors/genetics/*metabolism
MH  - Transplantation, Heterologous
MH  - YAP-Signaling Proteins
PMC - PMC4219672
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/11/05 06:00
MHDA- 2015/07/02 06:00
PMCR- 2014/11/04
CRDT- 2014/11/05 06:00
PHST- 2014/06/21 00:00 [received]
PHST- 2014/09/01 00:00 [accepted]
PHST- 2014/11/05 06:00 [entrez]
PHST- 2014/11/05 06:00 [pubmed]
PHST- 2015/07/02 06:00 [medline]
PHST- 2014/11/04 00:00 [pmc-release]
AID - PONE-D-14-27716 [pii]
AID - 10.1371/journal.pone.0109575 [doi]
PST - epublish
SO  - PLoS One. 2014 Nov 4;9(11):e109575. doi: 10.1371/journal.pone.0109575. 
      eCollection 2014.